Your browser doesn't support javascript.
loading
The CDK4/6 inhibitors biomarker landscape: The most relevant biomarkers of response or resistance for further research and potential clinical utility.
Antonarelli, Gabriele; Taurelli Salimbeni, Beatrice; Marra, Antonio; Esposito, Angela; Locatelli, Marzia Adelia; Trapani, Dario; Pescia, Carlo; Fusco, Nicola; Curigliano, Giuseppe; Criscitiello, Carmen.
Affiliation
  • Antonarelli G; Department of Oncology and Haemato-Oncology (DIPO), University of Milan, Milan, Italy; Division of Early Drug Development for Innovative Therapy, European Institute of Oncology, IRCCS, Milan, Italy.
  • Taurelli Salimbeni B; Division of Early Drug Development for Innovative Therapy, European Institute of Oncology, IRCCS, Milan, Italy.
  • Marra A; Division of Early Drug Development for Innovative Therapy, European Institute of Oncology, IRCCS, Milan, Italy.
  • Esposito A; Division of Early Drug Development for Innovative Therapy, European Institute of Oncology, IRCCS, Milan, Italy.
  • Locatelli MA; Division of Early Drug Development for Innovative Therapy, European Institute of Oncology, IRCCS, Milan, Italy.
  • Trapani D; Department of Oncology and Haemato-Oncology (DIPO), University of Milan, Milan, Italy; Division of Early Drug Development for Innovative Therapy, European Institute of Oncology, IRCCS, Milan, Italy.
  • Pescia C; Division of Pathology, European Institute of Oncology (IEO), IRCCS, Milan, Italy.
  • Fusco N; Department of Oncology and Haemato-Oncology (DIPO), University of Milan, Milan, Italy; Division of Pathology, European Institute of Oncology (IEO), IRCCS, Milan, Italy.
  • Curigliano G; Department of Oncology and Haemato-Oncology (DIPO), University of Milan, Milan, Italy; Division of Early Drug Development for Innovative Therapy, European Institute of Oncology, IRCCS, Milan, Italy.
  • Criscitiello C; Department of Oncology and Haemato-Oncology (DIPO), University of Milan, Milan, Italy; Division of Early Drug Development for Innovative Therapy, European Institute of Oncology, IRCCS, Milan, Italy. Electronic address: carmen.criscitiello@ieo.it.
Crit Rev Oncol Hematol ; 192: 104148, 2023 Dec.
Article in En | MEDLINE | ID: mdl-37783318
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Cyclin-Dependent Kinase 6 Type of study: Prognostic_studies Limits: Female / Humans Language: En Journal: Crit Rev Oncol Hematol Journal subject: HEMATOLOGIA / NEOPLASIAS Year: 2023 Document type: Article Affiliation country: Italy Country of publication: Netherlands
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Cyclin-Dependent Kinase 6 Type of study: Prognostic_studies Limits: Female / Humans Language: En Journal: Crit Rev Oncol Hematol Journal subject: HEMATOLOGIA / NEOPLASIAS Year: 2023 Document type: Article Affiliation country: Italy Country of publication: Netherlands